August 26, 2020 -- HiFiBio Therapeutics has submitted an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for novel SARS-CoV-2 neutralizing antibodies for the treatment of COVID-19 patients.
The differentiated antibody, Hfb30132A, has been developed with the company's single-cell profiling platform and evaluated in multiple preclinical studies. The anti-SARS-CoV-2 recombinant antibody is designed with specific sequences identified from B cells of a COVID-19 convalescent patient.
Hfb30132A binds to the viral spike protein and neutralizes several mutated strains of the virus, including the mutant D614G. The company expects the product to be used as a monotherapy for treatment and prevention against SARS-CoV-2.
Within the next six months HiFiBio expects to begin a phase I single-intravenous administration ascending dose clinical trial will assess the safety, tolerability, and pharmacokinetics of the products in healthy volunteers.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
